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SUMMARY. The aim of this study was to gain insight in
transmission routes of hepatitis C virus (HCV) infection
among never-injecting drug users (DU) by studying, inci-
dence, prevalence, determinants and molecular epidemiol-
ogy of HCV infection. From the Amsterdam Cohort Studies
among DU, 352 never-injecting DU were longitudinally
tested for HCV antibodies. Logistic regression was used to
identify factors associated with antibody prevalence. Part of
HCV NS5B was sequenced to determine HCV genotype and
for phylogenetic analyses, in which sequences were
compared with those from injecting DU. HCV antibody
prevalence was 6.3% and HCV incidence was 0.49/1000
PY. HIV-positive status, female sex and starting injection
drug use during follow-up (a putative marker of past injec-
tion drug use), were independently associated with HCV
prevalence. The main genotypes found were genotype 3a
(50%) and 1a (30%). Phylogenetic analysis revealed that
HCV strains in never-injecting DU did not cluster together
and did not differ from HCV strains circulating in injecting
DU. We found a higher HCV prevalence in never-injecting
DU than in the general population. Phylogenetic analysis
shows a strong link with the injecting DU population. The
increased risk could be related to underreporting of injecting
drug use or to household or sexual transmission from
injectors to noninjectors. Our ﬁndings stress the need for
HCV testing of DU who report never injecting, especially
given the potential to treat HCV infection effectively.
Keywords: cohort study, hepatitis C virus, noninjecting drug
users.
INTRODUCTION
Acute hepatitis C virus (HCV) infection is usually asymp-
tomatic, and leads to chronic infection in 50–80% of patients
[1]. Decades of chronic HCV infection can lead to liver cir-
rhosis and, in 1–5% of these patients, eventually to hepa-
tocellular carcinoma as well [2]. In recent years, treatment
success rates have substantially improved [3]. The most
important mode of HCV transmission is through exposure to
infected blood [1,4], and although sexual and household
transmission have been described, they appear to happen
only occasionally [5–7]. While never-injecting drug users
(DU) do not share needles and/or syringes, their HCV prev-
alence is still higher than in the general population. Some
studies suggest that HCV infection in never-injecting DU is
associated with the sharing of drug-use paraphernalia,
especially utilities used for consumption of crack, but others
could not conﬁrm these ﬁndings (reviewed in Ref. [8])
Alternatively, never-injecting DU might become infected
with HCV through needle-stick accidents, household trans-
mission, or sexual exposure. Recent review of research
describing HCV among noninjecting DU points to a sub-
stantial gap in our knowledge of HCV in never-injecting DU,
as no uniform risk factors could be identiﬁed [8].
The Amsterdam Cohort Study (ACS) among DU comprises
a large group of never-injecting DU. It was designed to
evaluate the sexual and blood borne transmission of HIV,
other blood borne pathogens, and sexually transmitted
diseases, as well as the determinants of transition to inject-
ing drug use. This design has the potential to determine
Abbreviations: ACS, Amsterdam Cohort Study; DU, drug users;
ELISA, enzyme linked immunosorbent assays; HCV, hepatitis C
virus; IQR, interquartile range; PY, person years; RT-PCR, reverse-
transcription polymerase chain reaction.
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among never-injecting DU. Additionally, we used phylo-
genetic analysis to investigate whether HCV strains isolated
from never-injecting DU were closely related to strains circu-
latingamonginjectingDU,orwhetherseparate introductions
had occurred through unrelated modes of transmission [9].
MATERIALS AND METHODS
The ACS among DU is an open, prospective cohort study
initiated in 1985 [9]. Participation in the ACS is voluntary,
and informed consent is obtained for every participant at
intake. Recruitment is ongoing and in recent years has been
directed in particular towards young DU. Both injecting and
noninjecting DU are included and visit the Amsterdam
Health Service every 4–6 months. Each study visit stan-
dardized questionnaires on (injecting) drug use and sexual
risk behaviour are administered by trained research nurses
and blood is drawn for prospective HIV testing and storage
of serum. To study HCV prevalence and incidence we ret-
rospectively tested stored serum from all participants having
at least two visits between December 1985 and November
2005 (n = 1276), using the ﬁrst available sample in each
case. Individuals who were HCV-negative at ACS entry
were tested for HCV antibodies at their last ACS visit before
November 2005. On ﬁnding HCV seroconversion (deﬁned
as the presence of HCV antibodies in a previously sero-
negative individual), we tested samples taken between these
two visits to determine the moment of seroconversion
(deﬁned as the midpoint between the last HCV seronegative
sample and the ﬁrst seropositive visit) [10]. Third genera-
tion commercial microparticle EIA system tests were used to
detect HCV antibodies (AxSym HCV version 3.0; Abbott,
Wiesbaden, Germany). 28.9% of the seropositive partici-
pants were tested at two study visits or more, all with
consistent positive HCV antibody test results. Presence of
HCV antibodies in all never-injecting DU was conﬁrmed
with Western blot (Deciscan HCV Plus immunoblot; BioRad,
Marnes la Coquette, France). All ACS samples were stored
at )80  C.
All ACS participants since 1985 (n = 1640) were tested
for HIV antibodies by enzyme-linked immunosorbent assays
(ELISA), since 2003 (AxSym HIV Ag/Ab Combo, Abbott,
Chicago, IL, USA), at each study visit. Results were con-
ﬁrmed by Western blot, since 1986, by HIV Blot version 2.2
(Genelab Diagnostics, pte Ltd, Singapore Science Park,
Singapore).
Statistical analysis
Anti-HCV antibody prevalence and incidence were calcu-
lated. Follow-up time was calculated from HCV-negative
study entry through HCV seroconversion, the moment of
starting injecting drug use, or November 2005, whichever
occurred ﬁrst.
Risk factors for the presence of HCV antibodies at study
entry were examined using logistic regression. All risk fac-
tors refer to the past 6 months, unless stated otherwise. They
included: general and demographic factors (sex, nationality,
ethnicity, calendar year of visit); drug use-related risk factors
(ever injecting drug use, years of regular heroin/cocaine/
amphetamines use, start of injecting drug use during ACS
follow up, alcohol use) and speciﬁcally cocaine-use-related
factors (years of regular cocaine use/cocaine snorting/basing
of cocaine); sexual risk behaviour (having sex with injecting
DU/commercial sex workers/men who have sex with men
since 1980, main sexual preference since 1980, number of
commercial sexual contacts since 1980, having a steady
sexual partner, having an injecting steady sexual partner,
HIV status of the steady sexual partner, condom use (with
steady sexual partner/casual partner/commercial contacts)
and other clinically relevant variables (subjects history of
HIV, jaundice, blood transfusion, tattoo, piercing).
Multivariate logistic regression models were built using
forward stepwise techniques. All variables with a P-value
£0.10 in univariate analysis were considered for entry into
the model. Statistical analysis was performed by use of
STATA (version 9.2; StataCorp, Collage Station, Texas, USA)
and spss (version 15.0; SPSS Inc., Chicago, IL, USA) soft-
ware. All statistical tests were two-sided; a P-value £0.05
was considered to be statistically signiﬁcant. Interaction and
confounding were checked between the variables in the ﬁnal
models and all variables with a univariate P-value £0.20.
Reverse-transcription polymerase chain reaction
(RT-PCR) methods
After HCV antibody screening, HCV-seropositive samples
were additionally tested for the presence of HCV RNA. RNA
isolation was performed on 100 lL of serum using the Tri-
Pure method (Roche Diagnostics, Almere, the Netherlands).
Each RNA isolate was used as input for two nested multiplex
RT-PCRs. The ﬁrst PCR, which targets the conserved HCV
core region, was devised as a genotyping system to differ-
entiate genotypes 1a, 1b, 2a, 2b, 3a, 4, 5a and 6a. The
second RT-PCR, which targets the NS5B region, was used for
phylogenetic analysis. Conditions and primers for both PCRs
have been described elsewhere [11].
Sequencing and phylogenetic analysis
The sequencing reaction and analysis were performed as
described earlier [11]. Brieﬂy, NS5B PCR products were
ethanol precipitated. Sense and antisense strands were sep-
arately cycle-sequenced using the BigDye Terminator system
(version 1.1; Perkin Elmer, Monza, Italy). Sequence products
were puriﬁed using DyeEx spin kits (Qiagen, Hilden, Ger-
many) and analysed on an ABI-310 automated sequencer
(Applied Biosystems, Nieuwekerk aan de IJssel, the Nether-
lands). Sequence alignment of the 436-bp NS5B fragment
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HCV in never-injecting DU 569was performed using the BioEdit software package [12].
Viral genotype was conﬁrmed after phylogenetic analysis of
the NS5B sequences obtained from subjects (GenBank
accession numbers EU410492 to EU410507) along with
established GenBank reference sequences [13] Mega soft-
ware (version 3.1; available at: http://www.megasoft-
ware.net) was used to construct a phylogenetic tree by the
neighbour-joining method, using the Tamura-Nei substitu-
tion model with c-distribution (a = 0.40). Bootstrap values
(n = 1000) were calculated to analyse the stability of tree
topology. HCV sequences obtained from DU who reported
never injecting were compared to all known HCV sequences




Among the 1276 DU who participated in the ACS and had
two or more visits between December 1985 and November
2005, 364 DU reported never having injected drugs before
study entry. Of these 364, 352 (96.7%) had serum available
for HCV testing. They were mainly male (69.3%) and of
Dutch nationality (305/352, 86.6%); of the 305 Dutch
participants 101 (33.1%) were of Surinamese ethnicity. Of
352 never-injecting DU, 154 preferred cocaine as their main
type of noninjected drugs (43.8%). Of the 352, 22 (6.3%,
95% CI 3.9–9.4%) were HCV antibody-positive at study
entry and 14/352 (4.0%, 95% CI 2.2–6.6%) DU were HIV-
positive (Table 1). The total HCV-negative and never-
injecting follow-up time was 2005 person years (PY); the
median follow-up time per participant was 6.4 years [inter-
quartile range (IQR) 3.01–11.3 years]. Only one never-
injecting DU seroconverted for HCV during follow up; the
HCV incidence was 0.049 per 100 PY (95% CI 0.01–0.35
per 100 PY). However, 47 never-injecting DU started
injecting during follow-up, of whom seven were HCV-posi-
tive at study entry and 23 seroconverted for HCV after
starting injection.
In addition to the observed HCV incidence, we calculated
an estimated incidence using prevalence data, assuming that
the duration of regular hard-drug use before study entry
equals the time of exposure to HCV. Information on the
number of years of regular cocaine/regular heroin use was
available for 285/352 individuals (81.0%), including 20/22
HCV positive never-injecting DU. The duration of regular use
of heroin or cocaine was used as the time of exposure. These
285 individuals had a total of 2539 PY of regular drug use.
The estimated time of HCV infection was deﬁned as the
midpoint of years of duration of regular use of hard drugs,
yielding an estimated incidence of 0.79 per 100 PY.
Assigning the estimated time of HCV infection to either the
start of regular hard drug use before study entry (maximum
estimated HCV incidence) or at study entry (minimum esti-
mated HCV incidence), changed the estimated HCV inci-
dence only slightly to 0.82 or 0.76 per 100 PY, respectively.
Associations with the presence of HCV antibodies
In univariate logistic regression (Table 2), the following
variables were signiﬁcantly associated with the presence of
HCV antibodies at entry in the ACS: female sex (OR 2.93,
95% CI 1.22–7.00) and starting injection during follow-up,
a putative marker of past injection drug use (OR 3.38,
95% CI 1.30–8.80). Although the association had only
borderline signiﬁcance, HIV-positive participants had a
higher risk of being HCV-positive (OR 4.58, 95% CI 1.18–
17.8, P = 0.053) (Table 2). No signiﬁcant association of
Table 1 General characteristics of never-injecting drug users





General drug use and HCV related characteristics
Median age (IQR) 30 (26–37) 30 (26–36)
Female sex 12/22 (54.4%) 96/330 (29.1%)
Dutch nationality 19/22 (86.4%) 286/330 (86.7%)
Homeless in the
past 6 months
0/14 (0%) 45/262 (17.2%)
Main type of drug used in the past 6 months
Heroin 6/20 (30%) 137/300 (45.7%)




1/20 (5%) 15/300 (5%)
Other – 7/300 (2.3%)
HIV-positive (%) 3/22 (13.6%) 11/330 (3.33%)
Ever tattoo 6/14 (43%) 91/194 (47%)
Ever piercing 2/14 (14%) 20/194 (10%)
Jaundice (ever) 2/8 (25%) 4/68 (6%)
Blood transfusion
(ever)
2/8 (25%) 5/67 (7.5%)
Follow-up characteristics
Median number of
visits to ACS (IQR)
15 (6–25) 12 (5–22)
Median years follow









HCV RNA+ 15 (68%) NA
Genotypes mainly related to injecting drug use
1a 4 (26.7%)*
3a 8 (53.3%)*
Genotypes mainly related to other risks
1b 2 (13.3%)*
2a 1 (6.7%)*
NA, not applicable; * % among all HCV RNA positive individuals.
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OR 95% CI P-value OR 95% CI P-value
Demographic variables
Age (per 10 years of increase) 1.29 0.75–2.23 0.36
Sex
Male 10/244 1 0.017 1 0.023
Female 12/108 2.93 1.22–7.00 2.85 1.15–7.05
Year of visit
1985–1992 13/125 1 0.063
1993–1998 4/114 0.31 0.10–1.00
1999–2005 5/113 0.40 0.14–1.16
Nationality
Dutch 19/305 1 0.97
Non-Dutch 3/47 0.97 0.28–3.43
Years of education after primary school
<3 3/31 1 0.36
3 4/35 1.20 0.25–5.86
4–5 3/78 0.37 0.071–1.96
>5 3/69 0.42 0.081–2.23
Alcohol use in the past 6 months
No 12/139 1 0.38
Yes 9/151 0.67 0.27–1.64
Drug use related risk factors
Main type of noninjecting drug used in past 6 months
Heroin 6/143 1 0.32
Cocaine 13/154 2.11 0.78–5.70
Cocktail of heroin/cocaine (i.e. speedball) 1/15 1.52 0.17–13.5
Frequency of noninjecting drug use (main drug used) in past 6 months
Multiple times daily 11/137 1 0.70
Once daily 1/20 0.60 0.07–4.94
Several times weekly, but less than daily 5/113 0.53 0.18–1.57
Several times monthly, but less than weekly 1/20 0.60 0.07–4.94
Once monthly 1/4 3.81 0.37–39.9
Less frequent 1/11 1.14 0.13–9.79
Non-injecting drug use of steady partner
Not applicable, no steady partner 13/169 1 0.35
No, never 4/35 1.55 0.47–5.06
Yes, now or ever 4/91 0.55 0.17–1.74
Start of injecting drug use during follow up
No 15/305 1 0.02 1 0.043
Yes 7/47 3.38 1.30–8.80 2.78 1.03–7.47
Years of regular heroin use
Less than 6 months (or never start) 1/49 1 0.10
6 months–5 years 3/66 2.29 0.23–22.6
‡5 years 16/170 4.99 0.64–38.6
Years of regular amphetamines use
Less than 6 months (or never start) 18/242 1 0.59
6 months or more 2/43 0.67 0.15–3.02
Cocaine related risk factors
Years of regular cocaine use
Less than 6 months (or never start) 3/45 1 0.61
6 months–5 years 6/112 0.79 0.19–3.32
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OR 95% CI P-value OR 95% CI P-value
‡5 years 11/128 1.31 0.35–4.95
Frequency of cocaine use in 6 months before ACS entry
No cocaine use 1/38 1 0.45
Once or more times monthly 1/28 1.37 0.082–22.9
Once or more times weekly 5/87 2.26 0.25–20.0
Once or more times daily 6/61 4.04 0.47–34.9
Sexual risk behaviour
Sex with injecting DU since 1980
No 8/149 1 0.59
Yes 4/54 1.41 0.41–4.89
Sex with commercial sex workers since 1980
No 5/94 1 0.80
Yes 7/114 1.16 0.36–3.80
Sex with MSM since 1980
No 8/172 1 0.16
Yes 4/36 2.56 0.73–9.02
Main sexual preference since 1980 (excluding contacts with commercial sex workers)
Exclusively heterosexual 15/285 1 0.18
Not exclusively heterosexual 5/47 2.14 0.74–6.20
Number of prostitution contacts in the 6 months preceding ACS entry (males and females)
No prostitution contacts 1/20 1 0.76
1–9 10/159 1.27 0.15–10.5
‡10 8/95 1.75 0.21–14.8
Prostitution contacts in the 6 months preceding ACS entry (males and females)
No 8/155 1 0.49
Yes 4/51 1.56 0.45–5.43
Steady partner in the 6 months preceding ACS entry
No 13/202 1 0.96
Yes 9/137 1.02 0.42–2.46
Steady partner that injects/injected drugs in the 6 months preceding ACS entry
Steady partner injects/injected drugs 2/35 1 0.98
Steady partner does/did not inject drugs 7/105 1.18 0.23–5.96
Not applicable, no steady partner 13/202 1.13 0.24–5.26
Last HIV test result of steady partner
Not applicable, no steady partner in the
6 months preceding ACS entry
20/283 1 0.88
Positive 1/10 1.46 0.18–12.1
Negative 0/37 – –
Unknown 1/20 0.69 0.088–5.44
Always use of condoms with steady partner
Not applicable, no steady partner in the
6 months preceding ACS entry
2/15 1 0.33
No 17/254 0.47 0.097–2.24
Yes 3/83 0.24 0.037–1.60
Always use of condoms with casual partners
Not applicable, no casual partners in the
6 months preceding ACS entry
1/51 1 0.07
No 18/212 4.64 0.60–35.6
Yes 3/89 1.74 0.18–17.2
Use of condoms with prostitution partners
Always use of condoms 3/36 1 0.47
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572 C. H. S. B. van den Berg et al.HCV with crack use was found, although the OR for cocaine
compared to heroin as the main type of drug used was 2.11
(95% CI 0.78–5.70) and the OR for one or more times daily
cocaine use was higher compared to less frequent cocaine
use in the 6 months preceding ACS entry.
In multivariate logistic regression, HIV-positive status (OR
5.07, 95% CI 1.21–21.3), female sex (OR 2.85, 95% CI
1.15–7.05) and starting injection during follow-up in ACS
(OR 2.78, 95% CI 1.03–7.47), were independently associ-
ated with the presence of HCV antibodies.
HCV RNA and phylogenetic analysis
Of 22 HCV-antibody positive never-injecting DU at ACS en-
try, 15 (68.2%) had detectable HCV RNA. The most frequent
HCV genotype found was 3a (53.3%), followed by genotype
1a (26.7%) (Table 1). HCV genotypes 1a and 3a are gen-
erally associated with injecting drug use, and in injecting DU
in the ACS they account for 252/317 (79%) of HCV infec-
tions for which genotyping was performed. Hence, the pro-
portion of injection-related HCV genotypes was comparable
among injecting DU and never-injecting DU ([11,14],
unpublished data). Figure 1 shows a phylogenetic tree of
HCV genotype 3a, comprising the 8 NS5B sequences ob-
tained from never-injecting DU together with all available
genotype 3a NS5B sequences (n = 65) from injecting DU
([11,14], unpublished data). Comparable to a pedigree, a
phylogenetic tree illustrates the evolutionary relationships
between genes or organisms or, in our case, the relationship
among aligned NS5B sequences of several HCV genotype 3a
viral variants. The more related two sequences are, the
smaller the horizontal distance between those sequences in
the tree. Based on phylogenetic analysis, sequences from
never-injecting DU could not be distinguished from those of
injecting DU. Sequences derived from never-injecting DU
were interspersed with those of injecting DU, and they were
not distinct phylogenetic isolates, nor did they form separate
never-injecting DU clusters. This was observed also in HCV
genotype 1a sequences (data not shown). The 3 never-
injecting DU not infected with HCV genotype 1a or 3a
harboured distinct strains of genotype 1b and 2a, which in
the Netherlands and Belgium are linked to blood transfusion
and nosocomial transmission rather than injecting drug use
[15,16]. The proportion of never-injecting DU infected with
these types (20%) was somewhat larger than the proportion
observed among injecting DU (9%) in the ACS, but the
difference was not statistically signiﬁcant (P = 0.26, Pearson
chi-square).
Interestingly, only one never-injecting (male) DU sero-
converted during follow-up despite denying injecting drug
use. He has regularly reported a steady sexual relationship
with an injecting (female) DU who also participates in
the ACS. She is a known injecting DU and became
chronically infected with HCV genotype 2b at least
2.7 years before her male never-injecting DU sexual part-
ner seroconverted for HCV. When comparing their two
HCV sequences, the sequences were 100% identical (data
not shown), making accidental exposure during household
contacts or sexual transmission the likely route of trans-





OR 95% CI P-value OR 95% CI P-value
Not always use of condoms 3/26 1.43 0.27–7.75
Not applicable, no prostitution partners 16/289 0.64 0.18–2.33
Other risk factors
HIV status
Negative 19/338 1 0.053 1 0.026
Positive 3/14 4.58 1.18–17.8 5.07 1.21–21.3
Tattoo (ever)
No 6/97 1 0.77
Yes 8/111 1.18 0.39–3.52
Piercing (ever)
No 12/186 1 0.65
Yes 2/22 1.45 0.30–6.95
Jaundice (ever)
No 6/70 1 0.11
Yes 2/6 5.33 0.80–35.4
Blood transfusion (ever)
No 6/68 1 0.16
Yes 2/7 4.13 0.66–26.1
OR = odds ratio, 95% CI = 95% conﬁdence interval.
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Fig. 1 NS5B Phylogenetic tree of pre-
valent HCV genotype 3a infections
among never-injecting drug users (DU)
(shaded) and ever-injecting DU in
Amsterdam, using the neighbour-join-
ing method based on Tamura-Nei sub-
stitution with c-distribution (a = 0.40).
Each isolate code contains the year of
sampling.
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In this cohort of never-injecting DU, the HCV prevalence was
6.3% (95% CI 3.7–8.8%). Although much lower than the
prevalence in injecting DU in the same cohort (83.5%, [10]),
this is substantially higher than in the general population in
The Netherlands (estimated to be 0.1–0.4%, [17]). In liter-
ature, the HCV prevalence in never-injecting DU ranges from
2.3 to 35.3% [8]. However many studies were not speciﬁ-
cally designed to measure HCV prevalence in never-injecting
DU and often did not include questions on noninjection drug
use risk factors for HCV.
The observed HCV incidence was very low at 0.049/100
PY, sixteen-fold lower than the HCV incidence estimated
from the prevalent cases at study entry (0.79/100 PY). This
suggests underreporting of past injecting drug use, which
may have led to misclassiﬁcation of injecting DU as never-
injecting DU. However, this estimated HCV incidence has
limitations: it does not take into account losses to follow-up
in the unknown cohort that the prevalence sample is sup-
posed to represent. Nor does it take differential recruitment
of rates of healthy and infected subjects into account.
However, when interpreted with caution, it could support
our hypothesis of underreporting of injection drug use.
Especially when injecting was incidental or stopped before
entry in the ACS, participants may deny past risk behaviour,
as has been described for HCV-positive blood donors in the
Netherlands [15].
Starting injection later during follow-up was indepen-
dently associated with a higher prevalence of HCV antibodies
at entry. Of 352 never-injecting DU, 47 switched to injecting
drug use after a median of 56 months (IQR 20–58 months).
Of the 47, seven were among the 22 found to be HCV
seroprevalent at entry. Again, this ﬁnding could suggest that
some injecting DU were misclassiﬁed as never-injecting DU.
They might have given socially desirable answers and denied
injecting, since it is perceived among DU as damaging to their
appearance and as overstepping a limit in the drug-using
scene in Amsterdam [18]. Alternatively, the DU who started
injecting during follow-up were already actively participating
in the scene of injecting DU and were therefore more likely to
become exposed to HCV through routes other than injecting
drug use, such as needle stick accidents. Since HIV and HCV
share transmission routes, the ﬁnding that HIV-positive
never-injecting DU had a higher HCV prevalence at entry
compared to HIV-negative participants, could imply that
HIV-positive status is an indicator of unreported injecting
drug use. On the other hand, HIV is transmitted sexually
much more efﬁciently than HCV, and HCV might be trans-
mitted more easily to and/or from HIV-positive individuals,
compared to HIV-negative individuals, since HIV co-infection
is associated with higher HCV RNA viral load [19].
Phylogenetic analysis revealed that the HCV sequences of
never-injecting DU did not cluster together, suggesting that
they were not a uniform group that became infected through
sharing of noninjection drug use paraphernalia. In contrast,
the noninjecting DU clustered together with the sequences
found in injecting DU in the ACS (Fig. 1), indicating that
they have close links with injecting DU and possibly
underreport injection drug use. So although these DU did not
report injecting drug use, they were infected from the pool of
injecting DU (Fig. 1). Although self-reported data on meth-
adone prescription in this cohort have been investigated and
shown to be consistent with data from the Dutch Central
Methadone Registration, self-reported data on sexually
transmitted diseases (STD) were shown to be less consistent
with diagnosis of such diseases [20,21]. In this study, based
on the ﬁndings from logistic regression and phylogenetic
analysis, some misclassiﬁcation of ever-injecting DU seems
likely in this never-injecting DU population.
Female sex was also associated with a higher HCV prev-
alence at entry, possibly indicating that women having sex
with an HCV-positive partner are at higher risk for sexual
transmission than men, as has been shown for HIV [22,23].
However, this gender difference has not yet been described
for HCV [24]. We did not ﬁnd an association between the
presence of HCV antibodies and sexual behaviour. Further-
more, we observed only one HCV seroconversion during
>2000 PY of follow-up, indicating that the risk of sexual
transmission – and also household transmission– is very
small as has been demonstrated in partner studies among
discordant heterosexual couples [25,26]. Unfortunately we
were not able to perform risk factor analysis based on just
one HCV seroconversion, but such analysis of incident cases
in a longitudinal study would be more robust than a cross-
sectional analysis of prevalent cases.
HCV has been detected on drug-use paraphernalia, and it
has been hypothesized that HCV can be transmitted via these
utilities (e.g. straws used for cocaine snorting) [27]. In line
with our phylogenetic ﬁnding of nonclustering of never-
injecting DU, we did not ﬁnd statistically signiﬁcant associ-
ations between cocaine use and the presence of HCV
antibodies. However, questions on snorting paraphernalia
were not included in the ACS questionnaires used in our
study period. Some questions (e.g. having a tattoo, having a
piercing) were added to the questionnaires in 2001 and thus
yield data for only a portion of participants included in this
study. A similar limitation holds true for the data on having
received a blood transfusion, a question not asked after
1989, shortly before HCV screening of donor blood was
introduced in developed countries. Moreover, never-injecting
DU might potentially have received a blood transfusion
when travelling to countries where transfusion is not yet
safe. Although the direction of the effect of having received a
blood transfusion was as expected (i.e. higher risk for those
who have received a blood transfusion compared to those
who did not), the main HCV genotype related to transmis-
sion by blood transfusion is genotype 1b, whereas the main
genotypes circulating among never-injecting and injecting
DU are 1a and 3a. Remarkably, in The Netherlands between
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(50%) of HCV RNA-positive new donor candidates who most
likely acquired HCV through a contaminated blood trans-
fusion in the past [15].
In conclusion, although the incidence of HCV was very
low in this study among never-injecting DU, the prevalence
was much higher than in the general population. In the
methadone outposts of the Amsterdam Health Service, HCV
screening is offered every year irrespective of recent injecting
drug use. Although, we could not distinguish whether the
increased risk of HCV infection in never-injecting DU was
related to underreporting of injection or to household or
sexual transmission, HCV strains of never-injecting DU
cluster with those found among injecting DU. HCV treat-
ment has improved substantially since 2000 and is effective
in up to 80–90% of patients [3]. Therefore, whatever the
route of transmission, it is clear that routine HCV testing and
treatment should be extended to both never-injecting and
injecting DU.
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